We previously reported that administration of denosumab, a human monoclonal antibody against the receptor activator of nuclear factor kappa-B ligand, increased BMD, suppressed bone turnover, and decreased plasma pentosidine in CLD patients with osteoporosis [36]. Here, TNFSF11 is linked to congenital secretory chloride diarrhea 1.